SCHEDULE: S.H.N. Financial Investments Reduces ENDRA Life Sciences Stake

S.H.N. Financial Investments Ltd. reported a 3.0% beneficial ownership in ENDRA Life Sciences Inc. through Series A Warrants, a significant reduction from a prior common stock holding.

Summary

• S.H.N. Financial Investments Ltd. reported beneficial ownership of 35,588 Series A Warrants in ENDRA Life Sciences Inc.
• These warrants represent 3.0% of ENDRA Life Sciences Inc.'s common stock, based on 1,166,441 shares outstanding as of October 16, 2025.
• This filing is an amendment to a previous Schedule 13G filed on June 14, 2024, which covered 7,921,648 shares of Common Stock purchased on June 4, 2024.
• Nir Shamir, Chief Executive Officer of S.H.N. Financial Investments Ltd., may be deemed to beneficially own these securities but disclaims beneficial ownership for other purposes.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: The significant reduction in reported beneficial ownership by S.H.N. Financial Investments Ltd. from common stock to a much smaller number of warrants suggests a less favorable view or a divestment of a substantial portion of their previous stake, which is generally a negative signal for the issuer.

Positives

• S.H.N. Financial Investments Ltd. maintains a passive investment stance, certifying that the securities are not held for the purpose of changing or influencing control of the issuer.

Negatives

• S.H.N. Financial Investments Ltd. has significantly reduced its reported beneficial ownership in ENDRA Life Sciences Inc., moving from 7,921,648 common shares reported in a previous filing to 35,588 Series A Warrants in this amendment.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Management Comments

• Nir Shamir, Chief Executive Officer of S.H.N. Financial Investments Ltd., disclaims beneficial ownership of these securities for all purposes other than being deemed to beneficially own them as CEO of the reporting person.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing is a routine disclosure of a passive investment stake by an institutional investor. It does not provide specific insights into broader industry trends or competitive landscape, but rather reflects an investor's position in ENDRA Life Sciences Inc.

Comparison to Industry Standards

• This filing is a standard Schedule 13G amendment, indicating a passive investment below the 5% threshold. It does not contain performance metrics or operational data that would allow for a direct comparison to industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The significant reduction in a major investor's reported stake could be perceived negatively, potentially impacting investor confidence and share price.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for ENDRA Life Sciences Inc. or S.H.N. Financial Investments Ltd. beyond the disclosure of ownership.

Key Dates

Recommendation

The substantial reduction in S.H.N. Financial Investments Ltd.'s reported beneficial ownership from over 7.9 million common shares to 35,588 Series A Warrants indicates a significant divestment or a change in investment strategy by a major holder. This action, particularly by an institutional investor, often signals a loss of confidence or a re-evaluation of the company's prospects, which could exert downward pressure on the stock price. While the filing itself is a passive disclosure, the underlying change in ownership is a strong negative signal for the stock.

Keywords

ENDRA Life Sciences, S.H.N. Financial Investments, Schedule 13G, Beneficial Ownership, Series A Warrants, Passive Investment, SEC Filing